Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.21 SEK | -2.44% | -6.50% | +173.29% |
Feb. 09 | Transcript : Ascelia Pharma AB, Q4 2023 Earnings Call, Feb 09, 2024 | |
Dec. 07 | Ascelia Pharma AB Announces Start of Image Reading Phase and Re- Confirms Phase 3 SPARKLE Results by May 2024 | CI |
Sales 2023 | - | Sales 2024 * | - | Capitalization | 319M 29.83M |
---|---|---|---|---|---|
Net income 2023 * | - | Net income 2024 * | -37 -3.46 | EV / Sales 2023 | - |
Net cash position 2023 | 21.86M 2.05M | Net cash position 2024 * | 18.5M 1.73M | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-7.35
x | Employees | 24 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 67.59% |
Latest transcript on Ascelia Pharma AB
1 day | -2.22% | ||
1 week | -6.29% | ||
Current month | +14.66% | ||
1 month | +19.87% | ||
3 months | +176.76% | ||
6 months | +140.05% | ||
Current year | +173.89% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 13-12-31 | |
Carin Linde
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-04 |
Andreas Norlin
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 69 | 17-05-31 | |
Niels Mengel
BRD | Director/Board Member | 76 | 99-12-31 |
Director/Board Member | 59 | 16-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 9.21 | -2.44% | 63 614 |
24-03-27 | 9.44 | -3.08% | 57,242 |
24-03-26 | 9.74 | -3.75% | 190,134 |
24-03-25 | 10.12 | -5.42% | 279,830 |
24-03-22 | 10.7 | +8.63% | 256,062 |
Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:45 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+173.89% | 30M | |
+9.16% | 45.97B | |
+54.42% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |